Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells

被引:52
作者
Friedrichsen, GM
Chen, WQ
Begtrup, M
Lee, CP
Smith, PL
Borchardt, RT
机构
[1] Royal Danish Sch Pharm, Dept Med Chem, DK-2100 Copenhagen, Denmark
[2] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[3] GlaxoSmithKline, Collegeville, PA 19426 USA
基金
美国国家卫生研究院;
关键词
L-valacyclovir; PepTl; Caco-2; cells; structure-transport relationships;
D O I
10.1016/S0928-0987(02)00047-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
L-Valacyclovir, a prodrug of acyclovir, is a substrate for the peptide transporter (PepTl) in the intestinal mucosa, which accounts for its higher than expected oral bioavailability. The substrate activity Of L-valacyclovir for PepTl is surprising, particularly when one considers that the molecule has the structural features of a nucleoside rather than a peptide. In an attempt to better understand the structure-transport relationships (STR) for the interactions Of L-valacyclovir with PepTl, analogs of this molecule with structural changes in the guanine moiety were synthesized and their substrate activity for PepTl in Caco-2 cell monolayers was determined. The analogs synthesized include those that had the guanine moiety Of L-valacyclovir substituted with purine, benzimidazole, and 7-azaindole. All three analogs (purine, benzimidazole, and 7-azaindole) exhibited affinity for PepTl in binding studies, but only the purine analog (as the L-valine ester) showed PepT I-associated transcellular transport across Caco-2 cell monolayers. The benzimidazole and 7-azaindole analogs (as their L-valine esters) were rapidly metabolized by esterase when applied to the apical surface of Caco-2 cells, which probably explains their low penetration as the intact prodrugs via PepTl. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 21 条
[1]   The oligopeptide transporter (Pept-1) in human intestine: Biology and function [J].
Adibi, SA .
GASTROENTEROLOGY, 1997, 113 (01) :332-340
[2]  
Bailey PD, 2000, ANGEW CHEM INT EDIT, V39, P506
[3]   AMINO-ACID ESTER PRODRUGS OF ACYCLOVIR [J].
BEAUCHAMP, LM ;
ORR, GF ;
DEMIRANDA, P ;
BURNETTE, T ;
KRENITSKY, TA .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1992, 3 (03) :157-164
[4]   MODIFICATIONS ON THE HETEROCYCLIC BASE OF ACYCLOVIR - SYNTHESES AND ANTIVIRAL PROPERTIES [J].
BEAUCHAMP, LM ;
DOLMATCH, BL ;
SCHAEFFER, HJ ;
COLLINS, P ;
BAUER, DJ ;
KELLER, PM ;
FYFE, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (08) :982-987
[5]  
CROOKS RJ, 1994, ANTIVIR CHEM CHEMOTH, V5, P31
[6]   Oral absorption of beta-lactams by intestinal peptide transport proteins [J].
Dantzig, AH .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :63-76
[7]  
De Vrueh RLA, 1998, J PHARMACOL EXP THER, V286, P1166
[8]   PHARMACOKINETICS OF ACYCLOVIR AFTER INTRAVENOUS AND ORAL-ADMINISTRATION [J].
DEMIRANDA, P ;
BLUM, MR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 :29-37
[9]   Valacycloviv: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2 [J].
Ganapathy, ME ;
Huang, W ;
Wang, H ;
Ganapathy, V ;
Leibach, FH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 246 (02) :470-475
[10]  
GAO J, 2000, CURRENT PROTOCOLS PH, P721